Figure 4.

Melatonin downregulates TRPC6 expression in MDA-MB-231 cells. MCF10A (A, E and I) and MDA-MB-231 cells (B–D, F–G and J–L) were treated for 48, 72, and 168 h with melatonin (10–1000 nM) or the vehicle (control) and lysed. Whole-cell lysates were subjected to 10% SDS-PAGE and western blotting with the anti-TRPC6 (A, B, E, F, I, and J), anti-PMCA (C, G, and K), anti-Orai1 (D, H and L), or anti-β-actin antibodies, as described in Experimental procedures. Blots are representative of five to ten separate experiments. Scatter plots represent TRPC6, Orai1, or PMCA expression. Analysis of statistical significance was performed using one-way ANOVA (0.001 < F < 2.04 and 0.14 < p < 0.99 for all panels, except (F) (F = 86.34; p < 0.0001) and (J) (F = 182.2; p < 0.0001)) with post-hoc Dunnett's test for (F and J) (∗p < 0.0001 compared with control).